# EDGAR Filing Document

**Accession Number:** 0001831915
**File Stem:** 0001193125-26-211948
**Filing Date:** 2026-5
**Character Count:** 22717
**Document Hash:** 0e8f7b5e17ae989752013613a594277a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-211948.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001193125-26-211948

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260507

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cytek Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001831915
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 472547526
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40632
- **FILM NUMBER:** 26953467

**BUSINESS ADDRESS:**
- **STREET 1:** 47215 LAKEVIEW BOULEVARD
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
- **BUSINESS PHONE:** (877) 922-9835

**MAIL ADDRESS:**
- **STREET 1:** 47215 LAKEVIEW BOULEVARD
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cytek BioSciences, Inc.
- **DATE OF NAME CHANGE:** 20201110

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported):

#### May 7, 2026

## Cytek Biosciences, Inc.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40632** | **47-2547526** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **47215 Lakeview Boulevard**<br> **Fremont, California** | **94538** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code: (877) 922-9835

#### (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, par value $0.001 per share | CTKB | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition.**  |

---

On May 7, 2026, Cytek Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. The press release is being furnished as Exhibit 99.1.

The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description of Exhibit** |
| 99.1 | [Press release dated May 7, 2026](d146722dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Cytek Biosciences, Inc.** | **Cytek Biosciences, Inc.** |
| Date: May 7, 2026 | By: | /s/ Wenbin Jiang |
|  |  | Wenbin Jiang, Ph.D.<br> President and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1** 

**Cytek Biosciences Reports First Quarter 2026 Financial Results** 

**FREMONT, Calif., May 7, 2026** (GLOBE NEWSWIRE) – Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026.

**Recent Highlights** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total revenue for the first quarter of 2026 was $44.1 million, representing a 6% increase compared to the
first quarter of 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Service revenue for the first quarter of 2026 was $15.4 million, representing a 15% increase compared to the
first quarter of 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total recurring revenue, comprised of service and reagent revenues, reached $18.4 million in the first
quarter. On a trailing-12-month basis, recurring revenue represented 35% of total revenue, up from 31% on a trailing-12-month basis as of the first quarter of 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Expanded to a total installed base of 3,789 Cytek instruments, adding 125 units in the first quarter of 2026

"Our first quarter growth stands out in a market that continues to experience global challenges, underscoring Cytek's technology leadership, the growth of our installed base, and the expansion of our recurring revenue streams," said Wenbin Jiang, CEO of Cytek Biosciences. "Rising instrument placements are expanding our installed base and driving higher demand for reagents and service, making recurring revenue an increasing share of total revenue. With focused execution and continued investment in our products, people, and infrastructure, we are well positioned for the year ahead."

**First Quarter 2026 Financial Results** 

Total revenue for the first quarter of 2026 was $44.1 million, a 6% increase compared to the first quarter of 2025. The increase in revenue was driven by strong revenue performance in the US and continued growth in service and reagent revenue worldwide.

GAAP gross profit was $21.3 million for the first quarter of 2026, a 5% increase compared to the first quarter of 2025. GAAP gross profit margin was 48% in the first quarter of 2026 compared to 49% in the first quarter of 2025. Adjusted gross profit margin, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles, was 51% in the first quarter of 2026 compared to 52% in the first quarter of 2025.

Operating expenses were $39.7 million for the first quarter of 2026, a 13% increase compared to the first quarter of 2025 due to increased general and administrative expenses, partially offset by a reduction in sales and marketing and research and development expenses.

Research and development expenses were $9.6 million for the first quarter of 2026, a 1% decrease compared to the first quarter of 2025.

Sales and marketing expenses were $11.6 million for the first quarter of 2026, a 7% decrease compared to the first quarter of 2025.

------

General and administrative expenses were $18.5 million for the first quarter of 2026, increasing 43% compared to the first quarter of 2025 due primarily to litigation-related expenses, outside consulting expenses and bad debt reserves.

Loss from operations in the first quarter of 2026 was $18.5 million compared to loss from operations of $15.0 million in the first quarter of 2025. Net loss in the first quarter of 2026 was $18.9 million compared to a net loss of $11.4 million in the first quarter of 2025.

Adjusted EBITDA loss in the first quarter of 2026 was $9.1 million compared to an adjusted EBITDA loss of $3.3 million in the first quarter of 2025, after adjusting for stock-based compensation expense and foreign currency exchange impacts.

Cash and marketable securities totaled $262.2 million as of March 31, 2026 compared to $261.5 million as of December 31, 2025, an increase of $0.7 million.

**2026 Outlook** 

Cytek Biosciences reaffirms its 2026 revenue guidance to be in the range of $205 million to $212 million, representing growth of 2% to 5% over full year 2025, assuming no change from current currency exchange rates.

**Webcast Information** 

Cytek will host a conference call to discuss its first quarter 2026 financial results on Thursday, May 7, 2026, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the conference call can be accessed at investors.cytekbio.com.

**About Cytek Biosciences, Inc.** 

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling<sup>™</sup> (FSP<sup>®</sup>) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes: its core FSP instruments, the Cytek Aurora<sup>™</sup>, Northern Lights<sup>™</sup>, Cytek Aurora<sup>™</sup> CS and Cytek Aurora<sup>™</sup> Evo systems; the Cytek Orion<sup>™</sup> reagent cocktail preparation system; the Enhanced Small Particle<sup>™</sup> (ESP<sup>™</sup>) detection technology; the flow cytometers and imaging products under the Amnis<sup>®</sup> and Guava<sup>®</sup> brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

------

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

**Statement Regarding Use of Non-GAAP Financial Information** 

Cytek has presented certain financial information in accordance with generally accepted accounting principles in the United States ("U.S. GAAP") and also on a non-GAAP basis for the three-month period ended March 31, 2026 and March 31, 2025. Management believes that non-GAAP financial measures, including "Adjusted gross profit," "Adjusted gross profit margin," and "Adjusted EBITDA loss," referenced in this release, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company's core operating results. Management uses non-GAAP measures to compare the company's performance relative to forecasts and strategic plans and to benchmark the company's performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company's operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.

**Forward-Looking Statements** 

------

with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section titled "Risk Factors" set forth in Cytek's most recent Annual Report on Form 10-K filed with the SEC on February 26, 2026, Cytek's Quarterly Report on Form 10-Q to be filed with the SEC on or about the date hereof and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek's forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release and the related conference call, webcast and presentation are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek's views as of any date subsequent to the date of this press release. Information contained on, or that is referenced or can be accessed through, our website does not constitute part of this document and inclusions of any website addresses herein are inactive textual references only.

**Media Contact:** 

Stephanie Olsen

Lages & Associates

(949) 453-8080

stephanie@lages.com

**Investor Contact:**

Paul Goodson

Head of Investor Relations

Cytek Biosciences

<u>pgoodson@cytekbio.com</u>

------

**Cytek Biosciences, Inc.** 

**Consolidated Balance Sheets** 

**(Unaudited)** 

---

| | | |
|:---|:---|:---|
| **(In thousands, except share and per share data)** | **March 31,<br>2026** | **December 31,<br>2025** |
|  **Assets** |  |  |
|  Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash and cash equivalents | $65665 | $90853 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Marketable securities | 196560 | 170676 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trade accounts receivable, net | 51903 | 62509 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inventories | 49791 | 48428 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses and other current assets | 15383 | 19530 |
|  Total current assets | 379302 | 391996 |
|  Property and equipment, net | 20469 | 18009 |
|  Operating lease right-of-use assets | 10643 | 11315 |
|  Goodwill | 16689 | 16697 |
|  Intangible assets, net | 15704 | 16821 |
|  Other noncurrent assets | 6306 | 6704 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total assets | $449113 | $461542 |
|  **Liabilities and stockholders' equity** |  |  |
|  Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trade accounts payable | $6741 | $6410 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Legal settlement liability, current | 2208 | 2495 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accrued expenses | 19781 | 23417 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other current liabilities | 22173 | 16978 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred revenue, current | 30032 | 28504 |
|  Total current liabilities | 80935 | 77804 |
|  Legal settlement liability, noncurrent | 6637 | 6786 |
|  Deferred revenue, noncurrent | 17672 | 18339 |
|  Operating lease liability, noncurrent | 13441 | 14042 |
|  Long-term debt | 386 | 525 |
|  Other noncurrent liabilities | 2398 | 2307 |
|  Total liabilities | 121469 | 119803 |
|  Stockholders' equity: |  |  |
|  Common stock, $0.001 par value; 1,000,000,000 authorized shares as of March 31, 2026 and December 31, 2025, respectively; 129,142,587 and 128,550,136 issued and outstanding shares as of March 31, 2026 and December 31, 2025, respectively | 129 | 129 |
|  Additional paid-in capital | 445750 | 441107 |
|  Accumulated deficit | (120604) | (101738) |
|  Accumulated other comprehensive gain | 2369 | 2241 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total stockholders' equity | 327644 | 341739 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities and stockholders' equity | $449113 | $461542 |

---

------

**Cytek Biosciences, Inc.** 

**Consolidated Statements of Operations and Comprehensive Loss** 

**(Unaudited)** 

---

| | | |
|:---|:---|:---|
|  | **Three months ended March 31,** | **Three months ended March 31,** |
| **(In thousands, except share and per share data)** | **2026** | **2025** |
|  Revenue, net: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Product | $28779 | $28110 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Service | 15356 | 13347 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total revenue, net | 44135 | 41457 |
|  Cost of sales: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Product | 15921 | 15529 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Service | 6960 | 5771 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total cost of sales | 22881 | 21300 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gross profit | 21254 | 20157 |
|  Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Research and development | 9604 | 9725 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sales and marketing | 11646 | 12509 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; General and administrative | 18467 | 12898 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total operating expenses | 39717 | 35132 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss from operations | (18463) | (14975) |
|  Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest expense | (262) | (291) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest income | 787 | 508 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other income, net | 565 | 3492 |
|  Total other income, net | 1090 | 3709 |
|  Loss before income taxes | (17373) | (11266) |
|  Provision for income taxes | 1493 | 136 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net loss | (18866) | (11402) |
|  Net loss, basic and diluted | $(18866) | $(11402) |
|  Net loss per share, basic | $(0.15) | $(0.09) |
|  Net loss per share, diluted | $(0.15) | $(0.09) |
|  Weighted-average shares used in calculating net loss per share, basic | 128704934 | 128339481 |
|  Weighted-average shares used in calculating net loss per share, diluted | 128704934 | 128339481 |
|  Comprehensive loss: |  |  |
|  Net loss | $(18866) | $(11402) |
|  Foreign currency translation adjustment, net of tax | 328 | (560) |
|  Unrealized loss on marketable securities | (201) | (65) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net comprehensive loss | $(18739) | $(12027) |

---

------

**Cytek Biosciences, Inc.** 

**Reconciliation of GAAP to Non-GAAP Measures** 

**(Unaudited)** 

---

| | | |
|:---|:---|:---|
|  | **Three months ended** | **Three months ended** |
| **(In thousands)** | **March 31, 2026** | **March 31, 2025** |
|  | (Unaudited) | (Unaudited) |
|  **GAAP gross profit** | $21254 | $20157 |
|  Stock based compensation | 729 | 1086 |
|  Amortization of acquisition-related intangible assets | 494 | 493 |
|  **Non-GAAP adjusted gross profit** | $**22477** | $**21736** |
|  **GAAP gross margin** | 48% | 49% |
|  **Non-GAAP adjusted gross margin** | 51% | 52% |
|  **GAAP net income** | $**(18866)** | $**(11402)** |
|  Depreciation and amortization | 2812 | 2881 |
|  Provision for (benefit from) income taxes | 1493 | 136 |
|  Interest income | (787) | (508) |
|  Interest expense | 262 | 291 |
|  Foreign currency exchange loss (gain) | 1152 | (1278) |
|  Stock based compensation | 4861 | 6629 |
|  **Non-GAAP adjusted EBITDA** | $**(9073)** | $**(3251)** |
|  Investment income | (1629) | (2261) |
|  **Non-GAAP adjusted EBITDA excluding investment income** | $**(10702)** | $**(5512)** |

---